Aligos Therapeutics Inc. (ALGS)
NASDAQ: ALGS
· Real-Time Price · USD
10.51
0.13 (1.25%)
At close: Oct 16, 2025, 3:59 PM
9.78
-6.95%
Pre-market: Oct 17, 2025, 04:22 AM EDT
Aligos Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
Revenue | 3.94M | 15.53M | 13.91M | 4.36M |
Cost of Revenue | n/a | 3.07M | 3.67M | 104.15M |
Gross Profit | 3.94M | 12.46M | 10.23M | -99.79M |
Operating Income | -89.15M | -88.13M | -97.58M | -128.32M |
Interest Income | n/a | 1.24M | 1.64M | 132K |
Pretax Income | -130.88M | -86.88M | -95.94M | -128.19M |
Net Income | -131.21M | -87.68M | -96.05M | -128.33M |
Selling & General & Admin | 22.83M | 30.62M | 26.41M | 28.53M |
Research & Development | 70.27M | 73.04M | 85.08M | 104.15M |
Other Expenses | n/a | n/a | n/a | n/a |
Operating Expenses | 93.1M | 103.66M | 111.49M | 132.68M |
Interest Expense | n/a | n/a | 1.64M | 132K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a |
Cost & Expenses | 93.1M | 102.96M | 111.49M | 132.68M |
Income Tax Expense | 331K | 795K | 106K | 143K |
Shares Outstanding (Basic) | 6.26M | 24.87M | 42.7M | 39.86M |
Shares Outstanding (Diluted) | 6.26M | 24.87M | 42.7M | 39.86M |
EPS (Basic) | -20.94 | -3.52 | -2.25 | -3.22 |
EPS (Diluted) | -20.94 | -3.52 | -2.25 | -3.22 |
EBITDA | -89.15M | -85.06M | -93.91M | -124.54M |
EBIT | -89.15M | -88.13M | -97.58M | -128.32M |
Depreciation & Amortization | n/a | 3.07M | 3.67M | 3.78M |
Source: Financial Modeling Prep. Financial Sources.